| Applications: |
CLIA |
| Reactivity: |
Human |
| Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
| Sensitivity: |
4.69pg/mL |
| Detection Limit: |
7.81~500pg/mL |
| Short Description: |
This human TNF kit is a highly sensitive in-vitro chemiluminescent immunoassay for the measurement of trace amounts of analytes in serum, plasma and other biological fluids. |
| Storage Instruction: |
If unopened the kit may be stored at 2-8°C for up to 1 month. If the kit will not be used within 1 month, store the components separately, according to the component table in the manual. |
| Assay Time: |
3.5h |
| Detection: |
Chemiluminescence |
| Gene Symbol: |
TNF |
| Gene ID: |
7124 |
| Uniprot ID: |
TNFA_HUMAN |
| Specificity: |
This kit recognizes Human TNF-Alpha in samples. No significant cross-reactivity or interference between Human TNF-Alpha and analogues was observed. |
| Sample Type: |
Serum, plasma and other biological fluids |
| Post Translational Modifications | The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space. The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1. O-glycosylated.glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid. Tumor necrosis factor, soluble form: The soluble form is demyristoylated at Lys-19 and Lys-20 by SIRT6, promoting its secretion. |
| Function | Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance. Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6. Promotes osteoclastogenesis and therefore mediates bone resorption. The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells. |
| Protein Name | Tumor Necrosis FactorCachectinTnf-AlphaTumor Necrosis Factor Ligand Superfamily Member 2Tnf-A Cleaved Into - Tumor Necrosis Factor - Membrane FormN-Terminal FragmentNtf - Intracellular Domain 1Icd1 - Intracellular Domain 2Icd2 - C-Domain 1 - C-Domain 2 - Tumor Necrosis Factor - Soluble Form |
| Database Links | Reactome: R-HSA-381340Reactome: R-HSA-5357786Reactome: R-HSA-5357905Reactome: R-HSA-5357956Reactome: R-HSA-5626978Reactome: R-HSA-5668541Reactome: R-HSA-6783783Reactome: R-HSA-6785807Reactome: R-HSA-75893 |
| Cellular Localisation | Cell MembraneSingle-Pass Type Ii Membrane ProteinTumor Necrosis FactorMembrane Form: MembraneSoluble Form: SecretedC-Domain 1: SecretedC-Domain 2: Secreted |
| Alternative CLIA Names | Tumor Necrosis Factor CLIA kitCachectin CLIA kitTnf-Alpha CLIA kitTumor Necrosis Factor Ligand Superfamily Member 2 CLIA kitTnf-A Cleaved Into - Tumor Necrosis Factor - Membrane Form CLIA kitN-Terminal Fragment CLIA kitNtf - Intracellular Domain 1 CLIA kitIcd1 - Intracellular Domain 2 CLIA kitIcd2 - C-Domain 1 - C-Domain 2 - Tumor Necrosis Factor - Soluble Form CLIA kitTNF CLIA kitTNFA CLIA kitTNFSF2 CLIA kit |
| Specificity | This kit recognizes Human TNF-α in samples. No significant cross-reactivity or interference between Human TNF-α and analogues was observed. |
| Reproducibility | Both intra-CV and inter-CV are |
Information sourced from Uniprot.org
| Item | Specifications | Storage |
| Micro CLIA Plate (Dismountable) | 96T: 8 wells ×12 strips strips | -20℃, 6 months |
| Reference Standard | 96T: 2 vials 48T: 1 vial | -20℃, 6 months |
| Concentrated Biotinylated Detection Ab (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃, 6 months |
| Concentrated HRP Conjugate (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃ (Protect from light), 6 months |
| Reference Standard & Sample Diluent | 1 vial, 20 mL | 2-8°C, 6 months |
| Biotinylated Detection Ab Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| HRP Conjugate Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| Concentrated Wash Buffer (25×) | 1 vial, 30 mL | 2-8°C, 6 months |
| Substrate Reagent A | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Substrate Reagent B | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Plate Sealer | 5 pieces | |
| Manual | 1 copy | |
| Certificate of Analysis | 1 copy | |
| Sample Type | Range (%) | Average Recovery (%) |
| Serum(n=8) | 100-113 | 107 |
| EDTA plasma(n=8) | 92-103 | 98 |
| Cell culture media(n=8) | 87-101 | 92 |
| | Intra-assay Precision | Intra-assay Precision | Intra-assay Precision | Inter-assay Precision | Inter-assay Precision | Inter-assay Precision |
| Sample | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 |
| n | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
| Mean (pg/mL) | 25.60 | 58.03 | 169.01 | 27.58 | 54.45 | 158.50 |
| Standard deviation | 2.69 | 5.50 | 13.54 | 2.46 | 6.40 | 14.99 |
| CV (%) | 10.51 | 9.48 | 8.01 | 8.92 | 11.75 | 9.46 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
